{"id":2603,"date":"2018-11-02T23:19:34","date_gmt":"2018-11-03T00:19:34","guid":{"rendered":"https:\/\/brtfinancial.com\/blog\/dental-practice-funding-more-news-novartis-abandons-effort-for-u-s-approval-of-biosimilar-rituximab\/"},"modified":"2018-11-02T23:19:34","modified_gmt":"2018-11-03T00:19:34","slug":"dental-practice-funding-more-news-novartis-abandons-effort-for-u-s-approval-of-biosimilar-rituximab","status":"publish","type":"post","link":"https:\/\/brtfinancial.com\/blog\/dental-practice-funding-more-news-novartis-abandons-effort-for-u-s-approval-of-biosimilar-rituximab\/","title":{"rendered":"Dental Practice Funding More News: Novartis abandons effort for U.S. approval of biosimilar rituximab"},"content":{"rendered":"<p><a href='' target='_blank'>  <\/a> [ad_1]<br \/>\n\t\t\t\t\t\t\t\t\t<br \/>Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used to treat certain cancer and rheumatoid arthritis.<\/p>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.reuters.com\/~ff\/reuters\/healthNews?a=R4FnGlNLtp0:-El2ntkiklI:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/reuters\/healthNews?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.reuters.com\/~ff\/reuters\/healthNews?a=R4FnGlNLtp0:-El2ntkiklI:F7zBnMyn0Lo\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/reuters\/healthNews?i=R4FnGlNLtp0:-El2ntkiklI:F7zBnMyn0Lo\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.reuters.com\/~ff\/reuters\/healthNews?a=R4FnGlNLtp0:-El2ntkiklI:V_sGLiPBpWU\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/reuters\/healthNews?i=R4FnGlNLtp0:-El2ntkiklI:V_sGLiPBpWU\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/reuters\/healthNews\/~4\/R4FnGlNLtp0\" height=\"1\" width=\"1\" alt=\"\" \/><br \/>\n\t\t\t\t\t\t\t\t\t<br \/>[ad_2]<br \/>\n\t\t\t\t\t\t\t\t\t<br \/><a href=\"http:\/\/feeds.reuters.com\/~r\/reuters\/healthNews\/~3\/R4FnGlNLtp0\/novartis-abandons-effort-for-u-s-approval-of-biosimilar-rituximab-idUSKCN1N72NA\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[ad_1] Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used to treat certain cancer and rheumatoid arthritis. [ad_2] Source link<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2603","post","type-post","status-publish","format-standard","hentry","category-dental-medical-practice-financing-programs"],"_links":{"self":[{"href":"https:\/\/brtfinancial.com\/blog\/wp-json\/wp\/v2\/posts\/2603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brtfinancial.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brtfinancial.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brtfinancial.com\/blog\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/brtfinancial.com\/blog\/wp-json\/wp\/v2\/comments?post=2603"}],"version-history":[{"count":0,"href":"https:\/\/brtfinancial.com\/blog\/wp-json\/wp\/v2\/posts\/2603\/revisions"}],"wp:attachment":[{"href":"https:\/\/brtfinancial.com\/blog\/wp-json\/wp\/v2\/media?parent=2603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brtfinancial.com\/blog\/wp-json\/wp\/v2\/categories?post=2603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brtfinancial.com\/blog\/wp-json\/wp\/v2\/tags?post=2603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}